Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001346098 | SCV001540271 | likely benign | not provided | 2025-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002547050 | SCV003660643 | uncertain significance | Inborn genetic diseases | 2021-02-19 | criteria provided, single submitter | clinical testing | The c.6295G>A (p.G2099S) alteration is located in exon 49 (coding exon 49) of the HSPG2 gene. This alteration results from a G to A substitution at nucleotide position 6295, causing the glycine (G) at amino acid position 2099 to be replaced by a serine (S). The p.G2099S alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001346098 | SCV003809303 | uncertain significance | not provided | 2019-10-01 | criteria provided, single submitter | clinical testing |